Originally developed to manage type 2 diabetes, these medications mimic the GLP-1 hormone, which plays a key role in regulating appetite, slowing gastric emptying, and enhancing feelings of fullness
Less motivated
GLP-1 receptors are present in the brain, cerebral blood vessels, pancreas, heart, gastrointestinal tract, adipose tissue, kidney, and muscles, and consequently affect a variety of systems and processes [38,39,40]
[18] Other research suggests that several pharmaceutical companies, including AstraZeneca, Zealand Pharma, Roche, and Amgen, are expected to enter the GLP-1 market, with multiple drug launches planned between 2027 and 2032
Cardiovascular diseases, though crucial, constitute a smaller share compared to the other two indications, reflecting a more specialized approach in GLP-1 drug applications for these diseases
La seguridad es un criterio crucial: protocolos de cifrado, auditoras independientes y certificaciones vlidas permiten identificar entornos confiables